Doxycycline directly targets PAR1 to suppress tumor progression

Doxycycline have been reported to exert anti-cancer activity and have been assessed as anti-cancer agents in clinical trials. However, the direct targets of doxycycline in cancer cells remain unclear. In this study, we used a chemical proteomics approach to identify the Protease-activated receptor 1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Zhong, Weilong, Chen, Shuang, Zhang, Qiang, Xiao, Ting, Qin, Yuan, Gu, Ju, Sun, Bo, Liu, Yanrong, Jing, Xiangyan, Hu, Xuejiao, Zhang, Peng, Zhou, Honggang, Sun, Tao, Yang, Cheng
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5370004/
https://ncbi.nlm.nih.gov/pubmed/28187433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15166
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars